AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5
slide-6
slide-7
slide-8

CCQ-L Tablet

Prescription Icon
Prescription Required

Marketer

Bharat Serums & Vaccines Ltd

Salt Composition

Letrozole (2.5mg)

Overview CCQ-L Tablet

Postmenopausal women with breast cancer may find relief with CCQ-L Tablets. This medication can be administered independently or alongside other therapies like surgery or radiation. It's also indicated for advanced breast cancer to inhibit metastasis. CCQ-L Tablets can be ingested with or without food, always following the physician's prescribed dosage and duration for optimal results. Dosage frequency varies based on the treatment goal, determined by your doctor to manage symptoms effectively. Continue the medication as directed. Common side effects include hot flushes, tiredness, excessive perspiration, and elevated cholesterol. Report any concerning symptoms to your physician; management strategies may be available. Prior to commencing treatment, inform your doctor of any pre-existing liver or kidney conditions, or a history of osteoporosis. Disclose all other medications currently in use, as interactions can affect CCQ-L's efficacy. Pregnancy or breastfeeding should also be reported. Your doctor may order blood tests to assess vitamin D levels and bone density before and throughout the treatment period.

Primary Ingredients of CCQ-L Tablet

No text provided. Please provide the text you want me to rephrase.

Uses of CCQ-L Tablet

Managing Breast Cancer

Major Benefits of CCQ-L Tablet:

Administer this medication precisely as prescribed by your physician, both in terms of dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. CCQ-L Tablets can be consumed with or without food; however, consistent daily timing is recommended.

Common Side effects of CCQ-L Tablet:

  • Dizziness
  • Fatigue
  • Weakness
  • Bone pain
  • Back pain
  • Night sweats
  • Joint pain
  • Nausea
  • Osteoporosis
  • Joint inflammation
  • Weight gain
  • Hot flushes
  • Edema (swelling)
  • Flushing (sense of warmth in the face, ears, neck and trunk)
  • Diaphoresis
  • Bone fracture
  • Hypercholesterolemia (high cholesterol)
  • Cough
  • Shortness of breath

How to use CCQ-L Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. CCQ-L Tablets can be administered with or without food, although consistent timing is recommended for optimal results.

How CCQ-L Tablet works:

CCQ-L tablets function as an aromatase inhibitor, reducing the body's estrogen production—a key female hormone. This lowered estrogen level can inhibit or halt the progression of certain estrogen-dependent breast cancers.

SAFETY ADVICE

AlcoholAlcoholSAFE

Alcohol consumption alongside CCQ-L Tablet poses no known adverse reactions.

PregnancyPregnancyUNSAFE

The use of CCQ-L Tablets is strongly contraindicated during pregnancy. Pregnant women should consult their physician; research in both animal and human studies has revealed substantial adverse effects on fetal development.

Breast feedingBreast feedingUNSAFE

Lactation and CCQ-L tablets are incompatible. Evidence indicates potential infant toxicity from this medication.

DrivingDrivingUNSAFE

Driving should be avoided if you experience drowsiness, dizziness, blurred vision, or reduced alertness after taking CCQ-L Tablets, as these are possible side effects.

KidneyKidneySAFE IF PRESCRIBED

CCQ-L Tablet poses no safety concerns for individuals with kidney disease and requires no dosage modifications. Data on its use in patients with end-stage renal disease is, however, scarce. Physician consultation is advised.

LiverLiverCAUTION

Individuals with hepatic impairment should exercise caution when using CCQ-L Tablet. Dosage modification may be necessary. Physician consultation is advised.

What if you forget to take CCQ-L Tablet :

Should you forget a CCQ-L Tablet dose, take it immediately. If your next dose is imminent, however, omit the missed dose and resume your usual dosing schedule. Never take a double dose.

Facts to Know About CCQ-L Tablet

LabelValue
Chemical Type Diphenylmethane-based Compound
Developing Habits No.
Treatment Category Cancer Medications

FAQs on CCQ-L Tablet

CCQ-L Tablets are aromatase inhibitors used to treat breast cancer in postmenopausal women.
CCQ-L Tablets are anti-estrogen medications. They work by inhibiting aromatase, the enzyme responsible for estrogen production, thereby lowering estrogen levels. This is beneficial because estrogen fuels the growth of certain breast cancers, known as estrogen-dependent cancers. Lowering estrogen levels can therefore help prevent cancer growth.
For advanced breast cancer or cancer that has spread, continue taking CCQ-L Tablet until tumor progression. Following tamoxifen or surgery, take CCQ-L Tablet for five years or until recurrence, whichever occurs first. Alternatively, a sequential treatment of two years of CCQ-L Tablet followed by three years of tamoxifen may be used.
While irbesartan and CCQ-L Tablet can be taken together, monitor your blood pressure closely as CCQ-L Tablet may raise it. Consult your doctor if blood pressure management becomes difficult.
While rare, CCQ-L Tablets may cause cataracts. Seek immediate medical attention if you develop blurred vision or eye irritation.
Experiencing hot flushes may indicate a common side effect of CCQ-L Tablet, related to decreased estrogen. These typically lessen as your body adapts, though some may persist throughout treatment and subside afterward. If bothersome, consult your doctor for management options.
While rare, serious side effects of CCQ-L Tablet may include stroke, angina, heart attack, blood clots, cataracts, osteoporosis, and severe skin reactions.
CCQ-L Tablets can lead to bone thinning (osteoporosis) because they lower estrogen levels. Your doctor may monitor your bone density before, during, and after treatment to detect osteoporosis.
The Ministry of Health and Family Welfare restricts CCQ-L Tablets to ovulation induction in women with anovulatory infertility.
CCQ-L Tablet
177